Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTERODINE

Next Previous
Trial Profile

A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTERODINE

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms EIGHT
  • Sponsors Pfizer

Most Recent Events

  • 26 Jul 2020 Results of pooled analysis from two placebo-controlled trials of fesoterodine over 12 weeks in group of men and women with overactive bladder over 65 years presented at the 35th Congress of the European Association of Urology
  • 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) characterising patient symptom response resented at the 48th Annual Meeting of the International Continence Society
  • 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examining efficacy and safety presented at the 48th Annual Meeting of the International Continence Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top